The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksUpdated•Originally published 17 April 2026•Updated 18 April 2026•

1 min read

Adaptive Biotechnologies Q1 Earnings Preview: Profitability Woes and Insider Selling

Key Facts

1Adaptive Biotechnologies is scheduled to report its Q1 2026 financial results on May 5, 2026.

2The company currently faces profitability challenges with a negative P/E ratio of -38.02 and negative operating cash flow.

about 2 months ago

Version History

Version 1about 2 months ago

What changed: Updated the volume of insider selling by COO Julie Rubinstein, adding specific details on the transaction value and the percentage of total holdings liquidated.

Adaptive Biotechnologies is set to release its Q1 2026 financial results on May 5, 2026, amid persistent fiscal challenges. The company continues to struggle with a negative P/E ratio of -38.02 and negative operating cash flow, weighing on market sentiment. Concerns have intensified following reports that President and COO Julie Rubinstein sold 57,180 shares for approximately $826,000 in transactions ending April 16. This liquidation represented 12.29% of her direct holdings, leaving her with 408,160 shares of common stock. Analysts remain focused on the firm's ability to stabilize cash burn and improve operational efficiency in a competitive sector. Consequently, the market maintains a cautious outlook as the biotechnology firm approaches its earnings call.